Olanzapine orodispersible tablet	Olanzapine conventional tablet	Serious adverse events	23914	24100	There were two serious adverse events (SAEs) reported in this study: appendicitis and completed suicide. None of those SAEs were considered as related to study drug by the investigators.
Olanzapine orodispersible tablet	Olanzapine conventional tablet	Compliance	574	703	Compliance and drug attitude were measured using the Drug Attitude Inventory (DAI-10) and Medication Adherence Form (MAF) scales;
Olanzapine orodispersible tablet	Olanzapine conventional tablet	Compliance	1034	1250	There was no significant change in DAI-10 with either formulation. MAF was above 75% in 94% vs. 93% of patients on ODC and OCT, respectively. Compliance as measured by tablet count was above 98% on both formulations.
Olanzapine orodispersible tablet	Olanzapine conventional tablet	Serious adverse events	23914	24099	There were two serious adverse events (SAEs) reported in this study: appendicitis and completed suicide. None of those SAEs were considered as related to study drug by the investigators
Olanzapine orodispersible tablet	Olanzapine conventional tablet	Patients with at least one adverse effect	23263	23383	The total number of patients with at least one AE while treated with ODT was 42 (16.8%) and with OCT 31 (12.5%) (P=0.31)
Olanzapine orodispersible tablet	Olanzapine conventional tablet	Efficacy	21775	21929	Results of a repeated measures ANCOVA, adjusted for compliance (MAF), did not indicate any difference in efficacy between treatment formulations (P=0.87).
Olanzapine orodispersible tablet	Olanzapine conventional tablet	Compliance	1176	1250	Compliance as measured by tablet count was above 98% on both formulations.
Olanzapine orodispersible tablet	Olanzapine conventional tablet	Preference	850	1033	A total of 175 patients answered a preference question: 106 (61%) preferred ODT and 48 (27%) preferred OCT (P<0.001 adjusted for treatment sequence); 21 (12%) expressed no preference.
Olanzapine orodispersible tablet	Olanzapine conventional tablet	Preference	850	998	A total of 175 patients answered a preference question: 106 (61%) preferred ODT and 48 (27%) preferred OCT (P<0.001 adjusted for treatment sequence)
